Physician profile
Harsha Rajashekar
NPI 1760668164
$27,345.90
in general payments reported to CMS, 2019-2025
38 companies · $3,548 in 2025
The $3,548 reported for 2025 was more than what 84% of Pain Medicine (Psychiatry & Neurology) providers received nationally (typical 2025 total: $405).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,174 · 2020: $1,960 · 2021: $4,804 · 2022: $5,823 · 2023: $4,432 · 2024: $2,605 · 2025: $3,548.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,166 · Travel and Lodging: $1,419.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,166.15 |
| Travel and Lodging | $1,418.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nevro Corp. | $6,410.25 | 2019-2024 | Senza |
| Painteq LLC | $4,189.72 | 2021-2024 | Painteq |
| Vertos Medical, INC. | $3,583.84 | 2019-2024 | Mild Device Kit |
| Boston Scientific Corporation | $3,353.69 | 2019-2025 | General - Pain Management, Wavewriter Alpha Prime 16, Intracept |
| Spinal Simplicity, LLC | $1,925.64 | 2025 | Ha Minuteman G3-R, Patriot Si |
| Collegium Pharmaceutical, INC. | $1,422.91 | 2019-2025 | Xtampza, Belbuca |
| Abbvie INC. | $1,216.62 | 2021-2025 | |
| Foundation Fusion Solutions, LLC | $669.01 | 2019-2025 | |
| Globus Medical, INC. | $658.65 | 2025 | Senza, Vyrsa V1, Vyrsa V1 |
| Stimwave Technologies Incorporated | $551.50 | 2021-2022 | |
| Medtronic, INC. | $407.64 | 2023-2024 | Intellis Adaptivestim |
| Allergan, INC. | $397.13 | 2019-2021 | |
| Relievant Medsystems, INC. | $357.22 | 2023 | Intracept |
| Medtronic USA, INC. | $348.21 | 2019-2020 | |
| Nalu Medical, INC. | $241.13 | 2021-2022 |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Surgentec | $224.87 | 2022 | |
| Amgen INC. | $192.31 | 2019-2021 | |
| Vertiflex, INC. | $190.56 | 2019 | |
| Lilly USA, LLC | $139.56 | 2019-2023 | Emgality, Reyvow |
| Genzyme Corporation | $133.91 | 2019 | |
| Neurometrix INC | $106.23 | 2023 | |
| Spr Therapeutics, INC | $102.58 | 2025 | Sprint Pns System |
| Bioventus LLC | $79.93 | 2024-2025 | Durolane |
| Trice Medical, INC. | $78.51 | 2023 | |
| Pacira Pharmaceuticals Incorporated | $43.88 | 2023-2024 | Zilretta, Iovera, Exparel |
| Mdd US Operations, LLC | $35.40 | 2019-2020 | |
| Saluda Medical Americas, INC. | $33.16 | 2025 | Evoke |
| Grifols USA, LLC | $32.39 | 2019-2020 | |
| Biodelivery Sciences International, INC. | $30.41 | 2021 | |
| Adamas Pharmaceuticals, INC. | $29.93 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $27.81 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $25.50 | 2019 | |
| Ge Healthcare | $21.24 | 2019 | |
| Abbott Laboratories | $20.92 | 2022 | |
| Genentech USA, INC. | $17.99 | 2019 | |
| Grt US Holding, INC. | $17.06 | 2022 | |
| Idorsia Pharmaceuticals US INC | $15.83 | 2023 | Quviviq |
| Lundbeck LLC | $12.76 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Harsha Rajashekar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.